Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN92,8592,94-2,37
Msft1,78
Nokia5,2445,272-0,19
IBM-0,42
Mercedes-Benz Group AG58,158,121,10
PFE-0,04
27.11.2025 18:00:28
Indexy online
AD Index online
select
AD Index online
 

  • 27.11.2025
Eckert & Ziegler (EUZG.DE, Xetra)
Závěr k 27.11.2025 Změna (%) Změna (EUR) Objem obchodů (EUR)
16,18 0,75 0,12 749 271
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace:
Popis společnosti
Obecné informace
Název společnostiEckert & Ziegler SE
TickerEUZ
Kmenové akcie:Ordinary Shares
RICEUZG.DE
ISINDE0005659700
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky30.09.2025
Počet zaměstnanců k 30.09.2025 1 112
Akcie v oběhu k 30.09.2025 62 573 961
MěnaEUR
Kontaktní informace
UliceRobert-Roessle-Str.10
MěstoBERLIN
PSČ13125
ZeměGermany
Kontatní osobaKarolin Riehle
Funkce kontaktní osobyInvestor Relations
Telefon49 309 410 840
Fax4930941084112
Kontatní telefon4930 941 084 138

Business Summary: Eckert & Ziegler SE is a Germany-based Company, which is a provider of isotope technology for medical, scientific and industrial use with focus on cancer therapy, industrial radiometry and nuclear-medical imaging. The Company operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Eckert & Ziegler SE revenues increased 4% to EUR224.1M. Net income applicable to common stockholders excluding extraordinary items increased 2% to EUR29.9M. Revenues reflect Medical segment increase of 15% to EUR119.7M. Net income was partially offset by Selling expenses increase of 9% to EUR21.6M (expense), Currency gains/losses increase of 63% to EUR2.6M (expense).
Odvětvová klasifikace
TRBC2009Medical Equipment / Supplies / Distribution
TRBC2012Medical Diagnostic & Testing Equipment
RBSS2004Medical Equipment, Supplies & Distribution
MGINDUSTRYChemical Manufacturing
MGSECTORBasic Materials
NAICSOther Basic Inorganic Chemical Manufacturing
NAICSPharmaceutical Preparation Manufacturing
NAICSSurgical Appliance and Supplies Manufacturing
NAICSOffices of Other Holding Companies
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007All Other Basic Inorganic Chemical Mfg
NAICS2007Surgical Appliance & Supplies Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997All Other Basic Inorganic Chemical Manufacturing
NAICS1997Surgical Appliance and Supplies Manufacturing
SICIndust'L Inorganic Chemicals, Nec
SICPharmaceutical Preparations
SICSurgical Appliances And Supplies
SICHolding Companies, Nec



  • Poslední aktualizace:
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Supervisory BoardAndreas Eckert6507.06.2023
Chairman of the Executive BoardHarald Hasselmann5808.06.202301.01.2017
Deputy Chairman of the Supervisory BoardHelmut Grothe6531.07.201731.07.2017
Member of the Group Executive Committee, Isotope Products SegmentJoseph Hathcock-
Member of the Group Executive Committee, Medical Segment (Operations)Gunnar Mann5801.01.2025
Member of the Group Executive Committee, Isotope Products SegmentAna Ramirez-01.01.2023
Member of the Executive Board, Isotope Products SegmentFranklin Yeager-